Latest news and press releases about Anteris Technologies Global Corp. (AVR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve.
Price
| Price | $8.37 |
| Market Cap | $814M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.56 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -77.66% |
| Return on Invested Capital | -41.63% |
| Return on Assets | -38.01% |
| Gross Margin | 36.98% |
| Operating Margin | -4738.36% |
| Net Margin | -4619.67% |
Related companies: ANIK · ARAY · ATLN · CYBN · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Devices
More sections of AVR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks